We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Clinical Characteristics of Registry Participants with Psoriatic Arthritis Initiating Guselkumab: An Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry.
- Authors
Mease, Philip J.; Ogdie, Alexis; Chakravarty, Soumya D.; Shiff, Natalie J.; Lin, Iris; McLean, Robert R.; Malley, Wendi; Spitzer, Rebecca L.; Kavanaugh, Arthur; Merola, Joseph F.
- Abstract
Background: The monoclonal antibody guselkumab is the first selective inhibitor of the interleukin-23 p19 subunit approved to treat adults with moderate-to-severe plaque psoriasis and active psoriatic arthritis (PsA). Given its recent approval for active PsA, data describing patients with PsA initiating guselkumab outside of clinical trials are limited. Objective: This analysis describes characteristics of patients with rheumatologist-diagnosed PsA initiating guselkumab in the US-based, prospective, observational CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. Methods: Demographics, lifestyle/disease characteristics, comorbidities, prior treatment, and disease activity were summarized for patients with PsA initiating guselkumab from registry inception through 30 September, 2021. Results: Of 113 patients initiating guselkumab, the majority were female (63%), obese (67%), had psoriasis (89%), and initiated guselkumab as monotherapy (81%). Common comorbidities were hypertension (32%), depression (30%), and diabetes mellitus (26%). Mean tender (6.8) and swollen (2.0) joint counts, clinical Disease Activity Index for PsA score (19.1), and 57% of participants with ≥ 3% body surface area affected by psoriasis indicated moderate disease activity. Axial involvement was identified in 49% of patients. Median patient-reported pain and fatigue visual analog scale scores (0–100) were 60 and 59, respectively. Prior to guselkumab, 76% of patients had received two or more biologic disease-modifying antirheumatic drugs; the last therapy prior to guselkumab was a biologic disease-modifying antirheumatic drug in 81% of patients. Conclusions: Registry participants with PsA initiating guselkumab had active peripheral joint and skin disease, with substantial pain and fatigue; a considerable proportion had axial involvement. Future studies will evaluate the effectiveness of guselkumab in this population.
- Subjects
PSORIATIC arthritis; SPONDYLOARTHROPATHIES; ANTIRHEUMATIC agents; BODY surface area; SKIN diseases; INTERLEUKIN-23; FATIGUE (Physiology)
- Publication
Drugs - Real World Outcomes, 2022, Vol 9, Issue 4, p617
- ISSN
2198-9788
- Publication type
Article
- DOI
10.1007/s40801-022-00326-2